Game Changer: First 100% Protective HIV Drug Approved

A 44-year battle against HIV may finally be turning the corner. The FDA has approved lenacapavir (Yeztugo), a twice-yearly injection offering nearly 100% protection against HIV infection. This capsid inhibitor prevents viral replication, marking a monumental breakthrough. Gilead Sciences is ensuring global access by offering affordable pricing and signing royalty-free licensing agreements with six generic manufacturers. This innovative approach, combined with partnerships like the one with the Global Fund to fight AIDS, aims to reach up to two million people in low- and lower-middle-income countries, signaling a potential turning point in the fight against the HIV epidemic.